Cargando…

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)

BACKGROUND: Individuals without prior immunity to a vaccine vector may be more sensitive to reactions following injection, but may also show optimal immune responses to vaccine antigens. To assess safety and maximal tolerated dose of an adenoviral vaccine vector in volunteers without prior immunity,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peiperl, Laurence, Morgan, Cecilia, Moodie, Zoe, Li, Hongli, Russell, Nina, Graham, Barney S., Tomaras, Georgia D., De Rosa, Stephen C., McElrath, M. Juliana
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2010
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2965084/ https://www.ncbi.nlm.nih.gov/pubmed/21048953 http://dx.doi.org/10.1371/journal.pone.0013579

Ejemplares similares

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
por: Pantaleo, Giuseppe, et al.
Publicado: (2019)

Use of adenovirus type-5 vectored vaccines: a cautionary tale
por: Buchbinder, Susan P, et al.
Publicado: (2020)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses
por: Hopkins, Kathryn L., et al.
Publicado: (2014)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090)
por: Fuchs, Jonathan D., et al.
Publicado: (2015)

Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults
por: Sedegah, Martha, et al.
Publicado: (2011)

Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and Adenovirus (Ad5) immune mice
por: Schuldt, Nathaniel J, et al.
Publicado: (2012)

Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
por: Fong, Youyi, et al.
Publicado: (2018)

Safety and Immunogenicity of an HIV Adenoviral Vector Boost after DNA Plasmid Vaccine Prime by Route of Administration: A Randomized Clinical Trial
por: Koblin, Beryl A., et al.
Publicado: (2011)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120
por: deCamp, Allan C., et al.
Publicado: (2017)

Poster Sessions 054-249
Publicado: (2004)

P13-05. Factors associated with pregnancy during the HVTN 503/Phambili trial, a phase IIB HIV trial of the Merck Ad-5 multi-clade HIV vaccine
por: Latka, M, et al.
Publicado: (2009)

P15-15. Advocates' perspectives on community engagement in the HVTN 505
por: Warren, M, et al.
Publicado: (2009)

P15-08. Did unblinding affect HIV risk behaviour and risk perception in the HVTN503/Phambili study?
por: Gray, GE, et al.
Publicado: (2009)

Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
por: Huang, Yunda, et al.
Publicado: (2015)

Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
por: Stieh, Daniel J, et al.
Publicado: (2022)

Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

P19-48. Induction of Ad5 neutralizing antibodies in placebo recipients during the Step Trial is not associated with risk of HIV infection
por: Spies, G, et al.
Publicado: (2009)

Correction: Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination
por: Cheng, Cheng, et al.
Publicado: (2012)

Opération piquet PO 2000-054
por: Royer, J P
Publicado: (2000)

Different memory T cell phenotypes are elicited by Ad5 and rare adenoviruses
por: Penaloza, P, et al.
Publicado: (2012)

Trivalent Adenovirus Type 5 HIV Recombinant Vaccine Primes for Modest Cytotoxic Capacity That Is Greatest in Humans with Protective HLA Class I Alleles
por: Migueles, Stephen A., et al.
Publicado: (2011)

Superior infectivity of the fiber chimeric oncolytic adenoviruses Ad5/35 and Ad5/3 over Ad5-delta-24-RGD in primary glioma cultures
por: Stepanenko, Aleksei A., et al.
Publicado: (2021)

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells
por: Fisher, Leigh, et al.
Publicado: (2019)

First-in-human phase 1 trial of the safety and immunogenicity of a recombinant adenovirus serotype 5 HVR48 (rAd5HVR48) HIV-1 vaccine
por: Walsh, SR, et al.
Publicado: (2012)

Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial Reveals an Association of Nonspecific Interferon-γ Secretion with Increased HIV-1 Infection Risk: A Cohort-Based Modeling Study
por: Huang, Yunda, et al.
Publicado: (2014)

Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age
por: Malkin, Elissa, et al.
Publicado: (2013)

rAd5/NYVAC-B is superior to NYVAC-B/rAd5 and is dependent on rAd5 dose for neutralizing antibody responses against HIV-1
por: Montefiori, DC, et al.
Publicado: (2012)

Discovery medicine – the HVTN's iterative approach to developing an HIV-1 broadly neutralizing vaccine
por: Martin, Troy M., et al.
Publicado: (2023)

Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions
por: Yang, Wei-Xiong, et al.
Publicado: (2016)

Evaluation of Novel Large Cut-Off Ultrafiltration Membranes for Adenovirus Serotype 5 (Ad5) Concentration
por: Nestola, Piergiuseppe, et al.
Publicado: (2014)

P054 Neurotransmitters of Sleep and Wake in Flatworms
por: Omond, S
Publicado: (2023)

Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-Based H5N1 Influenza Vaccine
por: Pandey, Aseem, et al.
Publicado: (2012)

Differential immunogenicity between HAdV-5 and chimpanzee adenovirus vector ChAdOx1 is independent of fiber and penton RGD loop sequences in mice
por: Dicks, Matthew D. J., et al.
Publicado: (2015)

Feasibility of recruiting high-risk women in the US for HIV vaccine efficacy trials (HVTN 906)
por: Koblin, B, et al.
Publicado: (2012)

Immunogenicity and Efficacy of a Recombinant Human Adenovirus Type 5 Vaccine against Zika Virus
por: Steffen, Tara, et al.
Publicado: (2020)

P054 Two effects of curcumin to Candida albicans
por: Kajiwara, Susumu, et al.
Publicado: (2022)

Adenovirus-Specific Immunity Following Immunization with an Ad5 HIV-1 Vaccine Candidate in Humans
por: O’Brien, Kara L., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_uc33jm426lhpdff1u4bng9armj